Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on June 14, 2015. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On June 14, 2015, the Board of Directors appointed Rajiv Shah, M.D., as a director, effective immediately. Dr. Shah was designated as an independent director and a Class I director with a term expiring at the 2016 annual meeting of shareholders. No other material changes to operations or financial status are reported in this document.
Guidance, Outlook, and Management Commentary
Dr. Shah is currently a Distinguished Fellow at Georgetown University's School of Foreign Service. His initial committee assignment will be determined at a later date. He will receive compensation consistent with the company's normal arrangements for non-employee directors. As part of his appointment, Dr. Shah was granted a stock option to purchase 15,000 shares of Omeros common stock. The filing states there are no understandings or arrangements pursuant to which he was appointed other than those disclosed.
Important Facts for Investors to Verify
- Confirmation of Dr. Shah's independence status under Nasdaq listing standards.
- Details of the non-employee director compensation policy referenced in the 2015 proxy statement.
- The specific terms and exercise price of the 15,000 share stock option granted to Dr. Shah.
- Future committee assignments for the new director.